Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 17:2022:3781109.
doi: 10.1155/2022/3781109. eCollection 2022.

Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors

Affiliations

Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors

Rui Huang et al. J Immunol Res. .

Abstract

Purpose: To investigate the prognostic value of blood markers in patients with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) treated with PD-1 inhibitors. Patients and Methods. We retrospectively collected and analyzed the clinicopathological data of 110 HBV-induced HCC patients treated with PD-1 inhibitors. Progression-free survival (PFS) and overall survival (OS) were scrutinized using Kaplan-Meier analysis and the log-rank test, and all potential risk factors were analyzed with univariate and multivariate Cox regression analyses.

Results: The mean OS and PFS were 6.5 and 5.5 months, respectively. According to Kaplan-Meier survival curves, elevated systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) correlated with decreased OS and PFS (all P < 0.05), and low lymphocyte-to-monocyte ratio (LMR) correlated with decreased PFS and OS (all P < 0.05). Per multivariate Cox regression analyses, SII, PLR, and portal vein tumor thrombus (PVTT) correlated independently with PFS (all P < 0.05), whereas SII, PLR, NLR, and portal vein tumor thrombus (PVTT) correlated with OS (all P < 0.05).

Conclusion: SII, PLR, and PVTT predicted OS and PFS in HCC patients who received PD-1 inhibitors and, therefore, could be useful predictors for risk stratification and individualized therapeutic decision-making for patients with HBV-induced HCC treated with PD-1 inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Receiver operating characteristic curves were generated to evaluate the discriminatory ability of the systemic immune-inflammation index, platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio. SII: systemic immune-inflammation index; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio.
Figure 2
Figure 2
The Kaplan–Meier survival curves indicated that elevated SII, PLR, and NLR were associated with decreased PFS (a–c). Conversely, decreased LMR was associated with decreased PFS (d).
Figure 3
Figure 3
The Kaplan–Meier survival curves indicated that elevated SII, PLR, and NLR were associated with decreased OS (a–c). Conversely, decreased LMR was associated with decreased OS (d).

Similar articles

Cited by

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. McGlynn K. A., Petrick J. L., London W. T. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clinics in Liver Disease . 2015;19(2):223–238. doi: 10.1016/j.cld.2015.01.001. - DOI - PMC - PubMed
    1. Zaragoza J., Caille A., Beneton N., et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. The British Journal of Dermatology . 2016;174(1):146–151. doi: 10.1111/bjd.14155. - DOI - PubMed
    1. Llovet J. M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine . 2008;359(4):378–390. doi: 10.1056/NEJMoa0708857. - DOI - PubMed
    1. Finn R. S., Ryoo B. Y., Merle P., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. Journal of Clinical Oncology . 2020;38(3):193–202. doi: 10.1200/jco.19.01307. - DOI - PubMed